Vivani Medical Completes Significant Stock Offering
Vivani Medical, Inc. (Nasdaq: VANI), a pioneering biopharmaceutical company specializing in advanced drug delivery solutions, has successfully closed its recent stock offering. This strategic move allows Vivani to continue its mission of developing ultra long-acting drug implants that facilitate better patient adherence to medications.
Details of the Offering
The company has completed a best-efforts registered direct offering of 6 million shares of its common stock at an offering price of $1.62 per share. Additionally, a concurrent private placement of approximately 3.7 million shares at the same price was completed, with Stewart Williams, the Chairman of the board, being a significant purchaser in this initiative. With total gross proceeds estimated at roughly $15.7 million, this infusion of capital will be instrumental in advancing the company's research and clinical development initiatives.
Strategic Use of Proceeds
Vivani intends to allocate the net proceeds from this offering primarily towards funding ongoing research and development efforts related to its innovative product candidates. This includes enhancing its renowned NanoPortal™ platform, which is engineered to deliver medications effectively over extended periods, ultimately improving patient compliance and treatment outcomes.
About Vivani's Innovative Solutions
At the core of Vivani's approach is the NanoPortal™ technology, which allows for steady drug release, enabling patients to avoid the common pitfalls associated with regular medication schedules. The development of GLP-1 based implants for the treatment of metabolic disorders, including obesity and type 2 diabetes, is especially promising. By mitigating issues related to the administration of daily oral medications or injections, Vivani's implants hold significant potential for enhancing patient experience and overall health outcomes.
A Growing Market for Medication Adherence
The issue of medication non-adherence is critical, with studies indicating that nearly half of patients do not follow their prescribed treatment plans. Vivani's solutions aim to combat this through their innovative drug delivery systems, providing a promising avenue to ensure that patients receive the full benefit intended from their medications.
The Role of ThinkEquity
In facilitating this offering, ThinkEquity served as the sole placement agent. Their expertise and experience in equity offerings have proved invaluable as Vivani takes this significant step towards bolstering its operational capacity.
Future Plans and Developments
Looking ahead, Vivani’s commitment to innovation remains steadfast. The funds raised will not only support ongoing clinical trials but also enhance collaboration efforts with various stakeholders in the biopharmaceutical landscape. This proactive approach will enable the company to stay at the forefront of drug delivery advancements.
Contact Information
For those interested in learning more about Vivani Medical, Inc. or its innovative solutions, here are the key contacts:
For Investor Relations Inquiries:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462
Investor Relations Contact:
Jami Taylor
Investor Relations Advisor
investors@vivani.com
(415) 506-8462
Media Contact:
Sean Leous
ICR Healthcare
Sean.Leous@ICRHealthcare.com
(646) 866-4012
Frequently Asked Questions
What is the main objective of Vivani Medical?
Vivani Medical focuses on developing innovative and long-acting drug delivery systems aimed at improving patient adherence to medications.
How much funding did Vivani Medical raise through the stock offering?
Vivani Medical raised approximately $15.7 million from the recent stock offering and private placement.
What is the NanoPortal™ technology?
NanoPortal™ technology is Vivani's proprietary platform designed to deliver drugs steadily over extended periods, improving patient experiences with medication.
Who acted as the placement agent for Vivani's stock offering?
ThinkEquity acted as the sole placement agent for the registered direct offering.
How does Vivani Medical plan to use the proceeds from the offering?
The proceeds will fund research and clinical development of its product candidates, along with supporting general corporate purposes.
